SmokingNCT07595055
Abuse Liability of Two Modern Oral Nicotine Pouched Products
A study testing Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette, Modern Oral Pouch Wintergreen-A 9 mg Nicotine and Modern Oral Pouch Wintergreen-B 9 mg Nicotine in people with Smoking and Smoking Behaviors, run by RAI Services Company.
Trial summary
This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine uptake (pharmacokinetics [PK]) during controlled monitored use and following ad libitum use of… Read more about this study
- Who is it for?
- Ages 21 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Smoking, Smoking Behaviors, Tobacco Use
- What is being tested?
- Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette, Modern Oral Pouch Wintergreen-A 9 mg Nicotine and Modern Oral Pouch Wintergreen-B 9 mg Nicotine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 15 Jun 2026to 30 Nov 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.
- Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.
- Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco and who also use ST (e.g., moist snuff).
- Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.
- Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.
- Reports daily use of ST products (i.e., moist snuff) and agrees to use the same UB ST throughout the study period. The UB moist snuff is defined as the reported moist snuff brand and style currently used most frequently by the participant.
Show all 21Show fewer
- Expired breath carbon monoxide (eCO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day 1).
- Positive urine cotinine test (i.e., ≥200 ng/mL) via dipstick at Screening and at Check-in Day 1.
- Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 ("How soon after you wake up do you smoke your first cigarette?") is either "Within 5 minutes" or "6-30 minutes" (Heatherton et al., 1991) OR response at Screening to "How soon after you wake up do you place your first dip?" is either "Within 5 minutes" or "6-30 minutes" from the Fagerström Test for Nicotine Dependance-Smokeless Tobacco (FTND-ST) (Ebbert et al., 2006).
- Willing to use Study IPs, their UB cigarette and UB moist snuff (Study IP Product S) during the study period.
- Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.
- Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.
- Examples of acceptable means of birth control are, but not limited to:
- Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy);
- physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide;
- abstinence;
- non-hormone releasing intrauterine devices (IUD);
- vasectomized partner; or
- post-menopausal and not on hormone replacement therapy.
- Agrees to an in-clinic confinement of five days (four nights).
- BMI within 18.0 to 40.0 kg/m2, inclusive (minimum weight of at least 50.0 kg at Screening)
Who cannot join
- Allergic to or cannot tolerate mint or wintergreen flavoring agents.
- Individuals or their family members that have ongoing litigation with tobacco company(ies).
- Have used electronic nicotine delivery system or tobacco heating device within the 30 days prior to screening.
- Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.
- History, presence of, or clinical laboratory test results indicating diabetes.
- Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.
Show all 23Show fewer
- History or presence of bleeding or clotting disorders.
- Any history of cancer, except for primary cancers of skin such as localized basal cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.
- Systolic blood pressure of > 160 mmHg or a diastolic blood pressure of > 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day 1.
- Hemoglobin level is < 12.5 g/dL for females or < 13.0 g/dL for males at Screening.
- Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
- Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.
- Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).
- Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within 30 days prior to signing the informed consent.
- Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.
- Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.
- Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.
- Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day 1.
- Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day 1.
- Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.
- Has used an investigational drug, device, biologic, or tobacco/nicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.
- Drinks more than 21 servings of alcoholic beverages per week.
- Determined by an investigator to be inappropriate for this study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: An In-Clinic Confinement Study to Assess Elements of Abuse Liability of Two Modern Oral Nicotine Pouched Products
This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine uptake (pharmacokinetics [PK]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.
Read the detailed description
Smokers who only use filtered menthol or non-menthol cigarettes and who also use loose or pouched moist snuff smokeless tobacco [Smokeless Tobacco (MST)] will be recruited into this AL study to evaluate elements of AL of two modern oral nicotine products (hereinafter, Study IPs) compared to combustible cigarettes (CC) and moist snuff tobacco.
Potential participants will complete a pre-screening telephone interview. They will complete a Screening Visit to assess their eligibility within 45 days prior to check-in and enrollment.
Starting on Day 1, participants will check-in at the clinical site to confirm eligibility. Eligible participants will be enrolled, randomized and confined in the clinic for 5 days (4 nights).
Participants will be randomized to a product use sequence (using a Williams Design) in which they will evaluate one IP in each of four separate daily Test Sessions, such that each participant will evaluate four IPs; Product B-A 9 mg, Product C-B 9 mg, participant's usual brand moist snuff tobacco [UB MST], and a high-AL comparator (participant's usual brand [UB] cigarette).
On Day 2 and continuing through Day 5, participants will participate in daily Test Sessions that will last approximately 8 hours, consisting of a 1-hour first use session immediately followed by a 7-hour ad libitum session. Each Test Session will include collection of both types of PD measures (subjective and physiological) and PK measures prior to, during, and following IP use. Following each test session, used IP (MO and UB MST pouched IPs only) will be collected, stored at -20°C, and shipped to a laboratory of the sponsor's choosing. For participants whose UB MST is loose moist snuff tobacco, a fresh unopened tin/can will be weighed immediately prior to the 'first use' portion of the session before the participant self-selects the amount of loose MST for their initial IP use. The lid will be replaced on the can/tin and weighed to the nearest 0.01g.
Immediately following the 1-hour 'first use' portion of the test session, a 7-hour ab libitum period will commence. Both types of PD (subjective and physiological) and PK measures will be measured during the 7-hour ab libitum period. The number, time, and duration of use of IPs that participants request will be recorded; every used IPs (MO and UB MST pouched IPs only) will be collected, stored at -20°C, and shipped to a laboratory of the sponsor's choosing. For participants whose UB MST is loose moist snuff, a fresh unopened tin/can will be weighed immediately prior to the participant self-selects the amount of loose UB MST for their test session, then the lid will be replaced to the can/tin and weighed to the nearest 0.01g. It is permissible to use the tin/can that was used for the earlier test session.
On the half day prior to each respective Test Session, a Product Acclimation Period will allow participants ad libitum use of the subsequent IP (at least two trial uses), except the participant's UB CC and UB MST, as per randomized sequence for product acclimation prior to use in the next day's Test Session. Participants can also use their UB cigarettes ad libitum, until the 12-hour tobacco and nicotine abstinence period begins prior to each Test Session, as long as the minimum use requirement for randomized IP is met. Used IP (only MO IPs and UB moist pouched snuff) from each of the Product Acclimation periods will be collected, stored at -20°C, and shipped to a laboratory of the sponsor's choosing.
Safety will be monitored throughout the study by the Principal Investigator (PI) (or designee) by assessing adverse experiences/events (AEs), vital sign measurements, physical examinations (including an oral examination), and clinical laboratory tests.
The Medical Monitor will be available for consultation during the study and for any follow-ups after study discharge.
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Being tested
- Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette, Modern Oral Pouch Wintergreen-A 9 mg Nicotine, Modern Oral Pouch Wintergreen-B 9 mg Nicotine, UB loose or pouched moist snuff
- Medical subject headings
- Smoking, Tobacco Use, Tobacco Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Usual Brand (UB) filtered, menthol or non-menthol combustible cigaretteOther
Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette
Modern Oral Pouch Wintergreen-A 9 mg NicotineOther
-A 9 mg Nicotine
Modern Oral Pouch Wintergreen-B 9 mg NicotineOther
-B 9 mg Nicotine
UB loose or pouched moist snuffOther
UB loose or pouched moist snuff
| Study group | Role | What they receive |
|---|---|---|
| Product usage order ASBC | Experimental | Subjects will use each of the 4 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session Receives: Other: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette; Other: Modern Oral Pouch Wintergreen-A 9 mg Nicotine; Other: Modern Oral Pouch Wintergreen-B 9 mg Nicotine; Other: UB loose or pouched moist snuff |
| Product usage order BACS | Experimental | Subjects will use each of the 4 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session Receives: Other: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette; Other: Modern Oral Pouch Wintergreen-A 9 mg Nicotine; Other: Modern Oral Pouch Wintergreen-B 9 mg Nicotine; Other: UB loose or pouched moist snuff |
| Product usage order CBSA | Experimental | Subjects will use each of the 4 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session Receives: Other: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette; Other: Modern Oral Pouch Wintergreen-A 9 mg Nicotine; Other: Modern Oral Pouch Wintergreen-B 9 mg Nicotine; Other: UB loose or pouched moist snuff |
| Product usage order SCAB | Experimental | Subjects will use each of the 4 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session Receives: Other: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette; Other: Modern Oral Pouch Wintergreen-A 9 mg Nicotine; Other: Modern Oral Pouch Wintergreen-B 9 mg Nicotine; Other: UB loose or pouched moist snuff |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUECPL 5-60
area under the effect curve (AUEC) for PL (VAS score-versus-time)
Measured: 5 minutes to 60 minutes
Emax PL
maximum effect (maximum PL VAS score after the start of IP use)
Measured: 60 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2026
- Study start15 Jun 2026 (estimated)
- Primary completion31 Jul 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SmokingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- RAI Services Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Brian Keyser, Study director, Reynolds American
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07595055
- Sponsor's protocol ID
- IHI263001
- Status last verified
- May 2026
- First submitted
- 6 May 2026
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No